WallStreetZenWallStreetZen

NYSE: RDY
Dr Reddys Laboratories Ltd Stock Forecast, Predictions & Price Target

Analyst price target for RDY

Based on 1 analyst offering 12 month price targets for Dr Reddys Laboratories Ltd.
Min Forecast
$80.00+12.49%
Avg Forecast
$80.00+12.49%
Max Forecast
$80.00+12.49%

Should I buy or sell RDY stock?

Based on 1 analyst offering ratings for Dr Reddys Laboratories Ltd.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RDY stock forecasts and price targets.

RDY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-01-29

1 of 1

Forecast return on equity

Is RDY forecast to generate an efficient return?
Company
N/A
Industry
0.07%
Market
20.28%

Forecast return on assets

Is RDY forecast to generate an efficient return on assets?
Company
N/A
Industry
0.04%

RDY revenue forecast

What is RDY's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$3.5B+17.39%
Avg 2 year Forecast
$3.7B+22.41%
RDY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RDY revenue growth forecast

How is RDY forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
10.69%
Industry
9.83%
Market
9.42%
RDY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RDY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RDY vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
RDY$71.12$80.00+12.49%Strong Buy
NBIX$131.74$142.13+7.89%Buy
VTRS$11.32$11.00-2.83%Sell
CTLT$56.08$55.42-1.18%Hold
TEVA$13.23$14.43+9.06%Strong Buy

Dr Reddys Laboratories Stock Forecast FAQ

Is Dr Reddys Laboratories Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSE: RDY) stock is to Strong Buy RDY stock.

Out of 1 analyst, 1 (100%) are recommending RDY as a Strong Buy, 0 (0%) are recommending RDY as a Buy, 0 (0%) are recommending RDY as a Hold, 0 (0%) are recommending RDY as a Sell, and 0 (0%) are recommending RDY as a Strong Sell.

If you're new to stock investing, here's how to buy Dr Reddys Laboratories stock.

What is RDY's revenue growth forecast for 2025-2026?

(NYSE: RDY) Dr Reddys Laboratories's forecast annual revenue growth rate of 10.69% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.83%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.42%.

Dr Reddys Laboratories's revenue in 2024 is $2,988,320,369.On average, 2 Wall Street analysts forecast RDY's revenue for 2025 to be $584,739,322,671, with the lowest RDY revenue forecast at $584,689,364,309, and the highest RDY revenue forecast at $584,789,281,034.

In 2026, RDY is forecast to generate $609,744,315,892 in revenue, with the lowest revenue forecast at $609,173,957,917 and the highest revenue forecast at $610,314,673,867.

What is RDY's forecast return on assets (ROA) for 2025-2026?

(NYSE: RDY) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 0.04%.

What is RDY's Price Target?

According to 1 Wall Street analyst that have issued a 1 year RDY price target, the average RDY price target is $80.00, with the highest RDY stock price forecast at $80.00 and the lowest RDY stock price forecast at $80.00.

The Wall Street analyst predicted that Dr Reddys Laboratories's share price could reach $80.00 by Jan 29, 2025. The average Dr Reddys Laboratories stock price prediction forecasts a potential upside of 12.49% from the current RDY share price of $71.12.

What is RDY's forecast return on equity (ROE) for 2025-2026?

(NYSE: RDY) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.